Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Recurrent or Metastatic Head and Neck Cancer
NCT00096512Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Started Oct 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00096512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096512.